Genetic Diseases, Inborn
40
3
6
25
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
14 trials with published results (35%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.0%
2 terminated out of 40 trials
92.6%
+6.1% vs benchmark
35%
14 trials in Phase 3/4
56%
14 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (40)
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
A Long-term Follow-up Study in Participants Who Received CTX001
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Health Economic Evaluation of Non-Invasive Prenatal Exclusion Diagnosis
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Prenatal Transplantation for Fetuses With Fanconi Anemia
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Effect of Benralizumab in Atopic Dermatitis
Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria
Evaluating Prenatal Exome Sequencing Study
Pilot Study of Cardiac MR in Patients With Muscular Dystrophy
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors
NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children